Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab

Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab

<p><strong>Objectives</strong></p><p>Treat to target recommendations for PsA state that the target of treatment should be remission or, at the very least, low disease activity. Different clinical indexes have been proposed to define these disease states including the mi...

Detaylı Bibliyografya
Asıl Yazarlar:	Coates, L, Rahman, P, Psaradellis, E, Rampakakis, E, Osborne, B, Lehman, A, Nantel, F
Materyal Türü:	Journal article
Baskı/Yayın Bilgisi:	Oxford University Press 2018

Benzer Materyaller

Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry
Yazar:: Emmanouil Rampakakis, ve diğerleri
Baskı/Yayın Bilgisi: (2020-08-01)

Golimumab for the treatment of psoriatic arthritis
Yazar:: H Yang, ve diğerleri
Baskı/Yayın Bilgisi: (2011-05-01)

Golimumab in the treatment of psoriatic arthritis: efficacy and safety
Yazar:: Tatiana Viktorovna Korotaeva, ve diğerleri
Baskı/Yayın Bilgisi: (2015-09-01)

Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry
Yazar:: Proton Rahman, ve diğerleri
Baskı/Yayın Bilgisi: (2020-09-01)

Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
Yazar:: M. Rossini, ve diğerleri
Baskı/Yayın Bilgisi: (2015-03-01)

Sustained very low disease activity and remission in psoriatic arthritis patients
Yazar:: Lubrano, E, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

Considerations for the definition of remission criteria in psoriatic arthritis
Yazar:: Mease, P, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Golimumab for Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis: Pharmacologic and Clinical Considerations
Yazar:: Sydney Moore McIntosh, ve diğerleri
Baskı/Yayın Bilgisi: (2023-07-01)

Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis
Yazar:: Melissa A Michelon, ve diğerleri
Baskı/Yayın Bilgisi: (2010-05-01)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
Yazar:: Ennio Lubrano, ve diğerleri
Baskı/Yayın Bilgisi: (2019-08-01)

Long-term effectiveness and safety of infliximab and golimumab in ankylosing spondylitis patients from a Canadian prospective observational registry
Yazar:: Proton Rahman, ve diğerleri
Baskı/Yayın Bilgisi: (2020-11-01)

Remission in psoriatic arthritis—where are we now?
Yazar:: Coates, L, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

What should be the primary target of "treat to target" in psoriatic arthritis?
Yazar:: Coates, LC, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort
Yazar:: van Mens, L, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Comparison of different remission and low disease definitions in patients with psoriatic arthritis and evaluation of their prognostic value
Yazar:: Coates, LC, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Novel concepts in psoriatic arthritis management: Can we treat to target?
Yazar:: Tucker, L, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
Yazar:: Coates, L, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
Yazar:: M. Elaine Husni, ve diğerleri
Baskı/Yayın Bilgisi: (2022-03-01)

Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials
Yazar:: Coates, L, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Mixed methods study of clinicians’ perspectives on barriers to implementation of treat to target in psoriatic arthritis
Yazar:: Dures, E, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

THE EFFECT OF GOLIMUMAB ON ARTERIAL STIFFNESS IN PATIENTS WITH RHEUMATOID ARTHRITIS
Yazar:: L. A. Knyazeva, ve diğerleri
Baskı/Yayın Bilgisi: (2018-03-01)

Evaluation of Improvement in Skin and Nail Psoriasis in Bio‐naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO‐VIBRANT Study
Yazar:: Philip Mease, ve diğerleri
Baskı/Yayın Bilgisi: (2020-11-01)

Using etanercept to maintain remission of psoriatic arthritis during pregnancy
Yazar:: Ibrahim A Al-Homood, ve diğerleri
Baskı/Yayın Bilgisi: (2014-01-01)

2-years outcomes of the treat-to-target strategy in early psoriatic arthritis
Yazar:: E. Yu. Loginova, ve diğerleri
Baskı/Yayın Bilgisi: (2022-11-01)

GOLIMUMAB SIGNIFICANTLY IMPROVES SELF-REPORTED PRODUCTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS
Yazar:: Wordsworth, P, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Difficult-to-treat psoriatic arthritis. Data from the All-Russian registry of patients with psoriatic arthritis
Yazar:: E. Yu. Loginova, ve diğerleri
Baskı/Yayın Bilgisi: (2024-10-01)

Use of a multidimensional RAPID3 questionnaire to assess the achievement of remission and minimal disease activity in patients with early psoriatic arthritis treated according to Treat-to-target strategy
Yazar:: E. Yu. Loginova, ve diğerleri
Baskı/Yayın Bilgisi: (2019-01-01)

Psoriatic arthritis: prospects for the future
Yazar:: Hackett, S, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab.
Yazar:: Taylor, P, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Measuring outcomes in psoriatic arthritis
Yazar:: Ogdie, A, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional study
Yazar:: Leung, Y-Y, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Psoriatic arthritis
Yazar:: FitzGerald, O, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Psoriatic arthritis: prospects for the future
Yazar:: Simon Hackett, ve diğerleri
Baskı/Yayın Bilgisi: (2022-03-01)

Golimumab therapy-induced indicators of X-ray inflammation progression and magnitude according to magnetic resonance imaging evidence in patients with rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis
Yazar:: Aleksandr Viktorovich Smirnov
Baskı/Yayın Bilgisi: (2013-06-01)

The road to personalised medicine in psoriatic arthritis
Yazar:: White, JPE, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Psoriatic arthritis: An up to date overview
Yazar:: Simon Hackett, ve diğerleri
Baskı/Yayın Bilgisi: (2020-01-01)

Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity
Yazar:: Ye, W, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries
Yazar:: Gorlier, C, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab
Yazar:: Sofia Lanz, ve diğerleri
Baskı/Yayın Bilgisi: (2021-08-01)

Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer
Yazar:: Ananaya Datta-Mitra, ve diğerleri
Baskı/Yayın Bilgisi: (2014-01-01)